摘要
目的 探讨拓扑异构酶Ⅱα（TOP2A）的表达与乳腺癌患者生存的相关性.方法 通过实时定量逆转录聚合酶链反应（quantitative RT-PCR）方法检测86例乳腺癌组织中的TOP2A基因表达量,应用荧光原位杂交（FISH）检测乳腺癌组织中TOP2A基因扩增,应用免疫组化（IHC）法检测TOP2A蛋白表达,并分析TOP2A基因表达量、TOP2A基因扩增与TOP2A蛋白表达的相关性.结果 86例乳腺癌患者中,TOP2A基因扩增11例,TOP2A基因缺失11例,TOP2A基因变异率为25.6%（22/86）;TOP2A蛋白表达的阳性率为66.3%（57/86）.TOP2A基因表达水平与蛋白表达水平显著相关（P=0.001）,TOP2A基因表达水平与乳腺癌患者的无进展生存期显著相关（P〈0.001）.TOP2A基因扩增与TOP2A蛋白阳件表达无显著相关性（P=0.211）.结论 TOP2A的基因定量表达水平为乳腺癌客观可靠的临床预后指标.
Objective The aim of this study was to assess the TOP2A RNA expression and die relationship of TOP2A protein expression with metastasis-free interval in breast cancer patients. Methods TOP2A expression was analyzed prior to surgery in 86 patients. The level of TOP2A gene amplification was analyzed by fluorescence in situ hybridization （FISH） , its RNA expression level with RT-PCR, and their correlation with TOP2A protein expression was assessed by immunohistochemistry （IHC）. The correlation between RNA expression level and metastasis-free interval in breast cancer patients was also analyzed. Results Aberrations （amplification or deletion） of TOP2A copy number was observed in 25.6% （22/86） of the cases. TOP2A protein expression was detected in 66. 3% （57/86） of the samples. There was a significant correlation between the TOP2A RNA expression and protein expression （P〈0.001）. TOP2A gene expression was significantly associated with the metastasis-free interval in the breast cancer patients （P =0.001）. There was no significant correlation between TOP2A gene amplification and TOP2A protein expression （P=0.211）. Conclusions TOP2A RNA level is an objective and reliable prognostic indicator in breast cancer.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2011年第5期363-366,共4页
Chinese Journal of Oncology
基金
基金项目：河南省自然科学基金（611040600）
关键词
乳腺肿瘤
拓扑异构酶Ⅱα
荧光原化杂交
实时定量PCR
基因扩增
预后
Breast neoplasms
Topoisomerase Ⅱ Alpha
Fluorescence in situhybridization
Quantitative RT-PCR
Gene amplification
Prognosis
